Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

21.41
+0.01000.05%
Post-market: 21.420.0100+0.05%17:50 EDT
Volume:2.37M
Turnover:50.71M
Market Cap:2.21B
PE:-20.59
High:21.44
Open:21.43
Low:21.40
Close:21.40
52wk High:21.46
52wk Low:5.64
Shares:103.30M
Float Shares:78.77M
Volume Ratio:0.71
T/O Rate:3.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0400
EPS(LYR):-1.0400
ROE:-22.74%
ROA:-14.64%
PB:5.01
PE(LYR):-20.59

Loading ...

BRIEF-Day One Biopharmaceuticals FY EPS USD -1.04

Reuters
·
Feb 25

Day One posts FY 2025 OJEMDA net product revenue of USD 155.4 million up 172%

Reuters
·
Feb 25

Day One Biopharmaceuticals Inc 2026 U.S. Net Product Revenue Projected at $225 Mln - $250 Mln

THOMSON REUTERS
·
Feb 25

Day One Biopharmaceuticals FY Cash & Investments USD 441.113 Million

THOMSON REUTERS
·
Feb 25

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

THOMSON REUTERS
·
Feb 25

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 24

Day One Biopharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Feb 21

Earning Preview: Day One Biopharmaceuticals Inc. this quarter’s revenue is expected to increase by 71.29%, and institutional views are bullish

Earnings Agent
·
Feb 17

Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Feb 16

Day One Biopharmaceuticals Inc. to report financial results and discuss corporate progress

Reuters
·
Feb 10

'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks

Benzinga_recent_news
·
Jan 21

Day One Biopharmaceuticals reinstated with a Buy at TD Cowen

TIPRANKS
·
Jan 13

Day One Biopharmaceuticals: Ojemda Outperformance and Advancing Pipeline Support Overweight Rating

TIPRANKS
·
Jan 13

Day One Biopharmaceuticals Inc : TD Cowen Reinstates Coverage With Buy Rating; Target Price $34

THOMSON REUTERS
·
Jan 13

A Look At Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Sales Guidance

Simply Wall St.
·
Jan 13

Day One Biopharma Shares Rise on Ojemda Sales Outlook

Dow Jones
·
Jan 12

Day One reports preliminary FY25 Ojemda net product revenue of $155.4M

TIPRANKS
·
Jan 12

Day One Biopharmaceuticals Projects 2026 OJEMDA Revenue of $225–$250 Million

Reuters
·
Jan 12

Day One Announces Preliminary 2025 Ojemda™ Net Product Revenue and Provides 2026 Net Product Revenue Guidance

THOMSON REUTERS
·
Jan 12

Mersana Therapeutics Shareholders to Receive $25 Per Share in Acquisition by Day One Biopharmaceuticals

Reuters
·
Jan 06